Shrikant Akolkar
Shrikant Akolkar is a pharmaceutical industry analyst at Nuvama Institutional Equities. He has provided insights on the competitive pricing strategies of weight-loss drugs such as Wegovy and Mounjaro in India, highlighting the potential impact of generic drug manufacturers on the market once Wegovy's active ingredient goes off patent.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Pakistan:
Shrikant Akolkar is a pharmaceutical industry analyst at Nuvama Institutional Equities who commented on the pricing of Wegovy.
5